



CS/Q2UFR/PR/2014-2015
November 15, 2014

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

To
The General Manager
Department of Corporate Services
Bombay Stock Exchange Ltd
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

Stock Code: SUVEN - EQ

Stock Code: 530239

Dear Sir/Madam,

Sub: Revised Press Release

.....

With reference to above subject, we have noticed some typographical errors in the Press Release of our Company relating to Un-audited Financial Results for the second quarter and six months ended 30th September, 2014 submitted by us on yesterday i.e. 14th November, 2014. Hence we are resubmitting revised Press Release along with the Investor Communication of the Company.

Inconvenience caused is regretted.

This is for your information and record.

Thanking You,
Yours faithfully,
For **SUVEN LIFE SCIENCES LIMITED**

A handwritten signature in black ink, appearing to read 'K Hanumantha Rao'.

K HANUMANTHA RAO
Company Secretary

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



News Release

Suven Revenue growth at 7.8% while PAT is down by 20% for the half year ended September, 2014

HYDERABAD, INDIA (14th November' 2014) – SUVEN Life Sciences Limited, a biopharmaceutical company specializing in drug discovery and developmental activities in Central Nervous System disorders, today announced its Un-audited financial results for the quarter ended 30th September 2014. The un-audited financial results were reviewed by the audit committee and approved by the Board of Directors in their meeting held on 14th November 2014 at Hyderabad.

Financial Highlights for the 2nd Quarter ended September' 2014:

Growth in revenue	Rs 1412 Mn vs Rs 1515 Mn	- down by 6.8%
Growth in PAT	Rs 248 Mn vs. Rs 455 Mn	- down by 45%
Growth in EBIDTA	Rs 398 Mn vs. Rs 715 Mn	- down by 44 %

Financial Highlights for the Half year ended September' 2014:

Growth in revenue	Rs 2839 Mn vs Rs 2633 Mn	- up by 7.8%
Growth in PAT	Rs 596 Mn vs. Rs 753 Mn	- down by 20%
Growth in EBIDTA	Rs 988 Mn vs. Rs 1177 Mn	- down by 16%

PAT for the current quarter was reduced by Rs. 32.2 Mn & for the Half year reduced by Rs.72.8 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. If the similar provisions of same quarter of previous years followed the PAT for this quarter would have been higher by Rs. 32.2 Mn to Rs 280.5 million and PAT for the half year would have been higher by Rs.72.8 million to Rs 668.5 million

Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. The repeat order for these supplies may happen after a gap of 12-18 months.

Suven's major thrust on innovative R&D in Drug Discovery continues with a spending of Rs 259 Mn (7.02% on revenue) for the half year ended September' 2014.

For more information on Suven please visit our Web site at <http://www.suven.com>

Risk Statement:

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive;

Suven Life Sciences Limited

CIN: L24110TG1989PLC009713

Registered Office: 8-2-334 I SDE Serene Chambers I 6th Floor I

Road No.5 I Avenue 7 I Banjara Hills I Hyderabad – 500 034 I Telangana I India

Tel: 91 40 2354 1142/ 3311/ 3315 Fax: 91 40 2354 1152 Email: info@suven.com website: www.suven.com



SUVEN Life Sciences

Communication to investors **September 2014**

14-Nov-14

2014-15 Q2 results



Risk statement

Except for historical information, all of the statements, expectations and assumptions, including expectations and assumptions, contained in this presentation may be forward-looking statements that involve a number of risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause these statements to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.



FINANCIAL QUICK VIEW

	Q2 Sep 14	HY Sep 14
Growth in revenue	-6.83%	7.79%
Growth in PAT	-45.48%	-20.90%
Growth in EBIDTA	-44.35%	-16.09%
Growth in Pre-R&D EBIDTA	-43.21%	-17.31%
Increase in R&D Costs	-38.67%	-22.84%
R&D to sales	7.78%	7.02%

14-Nov-14

2014-15 Q2 results



MAJOR PROFITABILITY RATIOS


	Q2 Sep 14	HY Sep 14
PAT to Income	17.59%	20.99%
EBIDTA to Income	28.19%	34.80%
Cash Flow to Income	21.63%	25.27%
Pre-R&D EBITDA to Income	35.97%	41.82%

14-Nov-14

2014-15 Q2 results



INCOME COMPARISON




14-Nov-14

2014-15 Q2 results




PROFIT COMPARISON





EBIDTA COMPARISON




Qtr Sep13 Qtr Sep14 HY Sep13 HY Sep14

14-Nov-14

2014-15 Q2 results



R & D – EXPENDITURE




14-Nov-14

2014-15 Q2 results



PRE-R&D EBIDTA




Qtr Sep13 Qtr Sep14 HY Sep13 HY Sep14

14-Nov-14

2014-15 Q2 results



PRE-R&D CASHFLOW



Qtr Sep13 Qtr Sep14 HY Sep13 HY Sep14



News releases

- Suven has **678** product patents for **18** inventions and **35** process patents
- Number of active CRAMS projects during period - **99**
- SUVN 502 completed Phase **1b** clinical trial in USA and preparation for entering Phase **2a** clinical trial has commenced
- SUVN-G3031 for Cognition in Alzheimer's Disease commenced Phase **1** Clinical Trial in USA under US-IND 123179
- Suven is selected as one of the "Best Under A Billion" companies by Forbes Asia 2014.
- Suven bags Pharmexcil's "Gold Patent Award" for NCE's and "Outstanding Export Performance Award" for Contract Research and Manufacturing.

14-Nov-14

2014-15 Q2 results



News releases

- PAT for the quarter was reduced by Rs. 32.2 Mn, & for the Half year reduced by Rs.72.8 Mn due to charge of additional depreciation computed as per Schedule II of the Companies Act 2013 effective April 1, 2014, shown as exceptional item in Profit & Loss Account. Had the similar provisions of same quarter of previous years would have been followed been, the PAT for this quarter would have been higher by Rs. 32.2 Mn. & as well as Rs.72.8 Mil for the half year ended 30/sept/2014.
- Lower revenue and PAT during this quarter compared to the same quarter last year is due to the absence of pre-launch supplies of intermediates for 3 of the NCE's which were done last year. The repeat order for these supplies may happen after a gap of 12-18 months since the last supplies.



Patent news release

- One (1) product patent from Eurasia (019496), One (1) product patent from Australia (2010337836), One (1) product patent from USA (8735423), one (1) product patent from South Korea (10-1410903), One (1) product patent from South Korea (10-1386354), one (1) product patent from China (CN102639526) and one (1) product patent from Canada (CA 2737282) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 to 2031.